Pallas vs Henry Meds: GLP-1 Telehealth Compared

Henry Meds was one of the first telehealth companies to make compounded GLP-1s widely accessible, and it remains one of the few — like Pallas — that hasn't gone branded-only in 2026. The two platforms even share a pricing philosophy: one bundled price that includes the provider and the medication, with no separate membership fee. So this comparison comes down to what's actually on the menu, where each platform operates, and what the fine print says when you want to change course.

This is an honest comparison. Pricing on both sides changes often; the figures here reflect each platform's published terms as of August 2026 — confirm current numbers on both sites before signing up.

The four differences that matter most

1. Pallas offers FDA-approved brands and compounded; Henry is compounded-only. Henry Meds does not offer brand-name Wegovy®, Ozempic®, Zepbound®, or Mounjaro® — its weight programs are compounded and generic medications (semaglutide injections and oral forms, liraglutide, phentermine). Pallas dispenses the FDA-approved brands and clinician-personalized compounded preparations, so a clinician can move you between tiers if your needs change without you switching platforms.
2. Injectable tirzepatide: Pallas has it; Henry doesn't. As of August 2026, Henry's tirzepatide offering is an oral dissolving tablet — its program list includes no injectable tirzepatide. Pallas offers compounded tirzepatide as the standard weekly injection: $179 for your first month, then $897 every 12 weeks ($299/mo average). Cancel anytime.
3. State coverage. Pallas serves all 50 states plus Washington, D.C. As of August 2026, Henry's weight-management enrollment covers 40 states plus D.C. — its intake doesn't list Alabama, Alaska, Arkansas, Hawaii, Louisiana, Mississippi, Missouri, South Carolina, Tennessee, or West Virginia.
4. The exit terms. Both platforms bill on a subscription. Through Pallas you can cancel anytime, self-serve, and you're refunded in full if a clinician decides treatment isn't right for you. Henry's published terms state prescriptions are final sale, and canceling a multi-month plan early may require paying out the remaining balance unless it's for medical reasons. Neither is hidden — read both before committing anywhere.

Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.

Quick comparison

What Henry Meds does well

It stayed the course on compounded access. Henry built its brand on making compounded GLP-1 therapy simple and bundled, and it still does that — one subscription price including the provider visit, medication, and supplies, with no membership fee. Structurally, that's the same philosophy Pallas uses, and it's genuinely patient-friendly compared to membership-plus-medication models.

Oral options. Henry offers compounded oral semaglutide (dissolving tablets and sublingual drops) and an oral tirzepatide tablet — formats some patients prefer over injections. Pallas's compounded line is weekly injections; if a needle is a dealbreaker and a clinician judges an oral form appropriate for you, Henry has formats Pallas doesn't.

A lower advertised floor — with prepay. Henry's "starts at $179/month" pricing is real but applies to specific programs paid in full up front (its 3-month oral semaglutide program, and its 12-month prepaid injection rate works out to about $197/month). Its month-to-month compounded semaglutide injection is $297/month. If you're comfortable prepaying six or twelve months to unlock a lower rate, that's a real option Pallas doesn't offer.

An established operation. Henry Meds has operated since 2022, publishes its full program terms, and displays a LegitScript seal on its site.

What Pallas does differently

Both tiers on one platform. Pallas dispenses FDA-approved Wegovy®, Ozempic®, Zepbound®, and Mounjaro® alongside clinician-personalized compounded semaglutide and tirzepatide injections. If your clinician decides a brand is the right fit later — or a compounded preparation is — you don't have to change platforms. Henry can't prescribe a brand-name GLP-1 at all.

Injectable tirzepatide. For patients specifically seeking tirzepatide as the standard weekly injection, Pallas offers it: $179 for your first month, then $897 every 12 weeks ($299/mo average). Cancel anytime. Henry's tirzepatide is an oral tablet only.

Flat monthly-equivalent pricing without prepay lock-in. Compounded semaglutide injection through Pallas is $139 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime. That per-month average is below Henry's $297 month-to-month rate and in the same range as Henry's best 12-month prepaid rate — without paying $2,000+ up front or committing to a payout-on-cancellation term. The price is flat at every dose, and you can cancel anytime.

Every state, one experience. Pallas serves all 50 states and D.C., with asynchronous care in most of them and one video visit where state law requires it. Henry serves 40 states + D.C. as of August 2026 — if you live in (or might move to) one of the others, that decides the comparison by itself.

Patient-friendly exit terms. Full refund if a clinician decides treatment isn't right for you; self-serve cancellation anytime in the portal; no balance payout on cancellation.

A free companion app. The Pallas companion app (Protein & GLP-1 Tracker, iOS and Android) tracks protein, steps, weight trend, and dose reminders — free, no subscription.

The pricing math, honestly

Both platforms bundle the provider and medication into one price with no membership fee — the comparison is the number itself and the commitment behind it.

• Month-to-month: Pallas compounded semaglutide averages out below Henry's $297/month rate, and Pallas's first month is lower than any Henry entry point for injectable semaglutide.
• Prepaid: Henry's 12-month paid-in-full injection rate (~$197/month) lands almost exactly at Pallas's per-month average — but requires paying the year up front, and early cancellation on multi-month plans may mean paying out the balance. Pallas has no prepay tier and no payout clause.
• Oral forms: Henry's 3-month prepaid oral semaglutide (~$179/month paid in full) is its true floor. Pallas doesn't offer a compounded oral form, so if that's your pick, compare Henry's oral program terms directly.

The honest summary: for injectable therapy, Pallas is at or below Henry's best rates without the prepay commitment. For oral compounded forms, Henry has options Pallas doesn't. For brand-name medications or injectable tirzepatide, Henry isn't an option.

Who should pick which

Henry Meds is probably the better fit if:

• You specifically want a compounded oral form (dissolving tablet or sublingual) and a clinician judges it appropriate
• You're comfortable prepaying 6–12 months to unlock the lowest rate
• You live in one of its 40 covered states and want a straightforward bundled subscription

Pallas is probably the better fit if:

• You want the full toolkit — FDA-approved brands and clinician-personalized compounded injections — on one platform
• You want injectable tirzepatide, which Henry doesn't offer
• You want month-to-month flexibility: cancel anytime, no prepay, no balance payout, full refund if a clinician doesn't prescribe
• You live in a state Henry doesn't serve (including Alabama, Arkansas, Hawaii, Louisiana, Mississippi, South Carolina, and Tennessee)
• You want a free companion app (iOS and Android) for protein, steps, and dose tracking

Switching between them

Transitions are straightforward. Bring your medication name, current dose, and titration history (export or screenshot your records before canceling anywhere), and a new provider picks up from your current dose — no restart of titration unless you've been off medication for more than four weeks. If you're switching from an oral form to a weekly injection (or considering the change), raise it in the intake so the clinician can plan the transition. For the clinical side of choosing between molecules, see semaglutide vs tirzepatide.

References

Platform pricing and program details reflect each company's publicly published terms as of August 2026 and change frequently — confirm current numbers on each platform's site before enrolling. The regulatory basis for compounded preparations is summarized by the FDA.

1. Henry Meds. Program terms and pricing, as published August 2026 (compounded semaglutide injection $297/month month-to-month; prepaid tiers lower; state list from the live enrollment flow).
2. U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. 2025.

Bottom line: Henry Meds and Pallas share the best structural idea in GLP-1 telehealth — one bundled price, no membership fee — but differ on almost everything inside it. Henry is compounded-only with oral options and prepay discounts, serves 40 states, and holds you to multi-month terms. Pallas offers FDA-approved brands plus compounded weekly injections (including injectable tirzepatide, which Henry doesn't carry), serves all 50 states and D.C., prices flat at every dose with no prepay, and lets you cancel anytime with a full refund if a clinician doesn't prescribe. If an oral compounded form at a prepaid rate is what you want, price Henry's programs carefully; for everything else, Pallas is the more flexible structure.